Vaginal Pessary Market Size & Share [2033]

Vaginal Pessary Market Overview

The Keyword Market size was valued at USD 283.6 million in 2024 and is expected to reach USD 428.64 million by 2033, growing at a CAGR of 4.7% from 2025 to 2033.

The vaginal pessary market is a specialized segment of the global women’s health device industry, designed primarily for the non-surgical management of pelvic organ prolapse (POP) and stress urinary incontinence (SUI). In 2024, more than 25 million women globally used pessaries as part of their therapeutic care regimen, representing a significant and growing population seeking non-invasive alternatives to pelvic floor surgery. Among these users, nearly 64% were aged 60 and above, reflecting the rising prevalence of POP in aging populations.

The increasing preference for outpatient treatment and lower healthcare expenditure has supported the market’s expansion. Clinics, primary care units, and gynecological practices collectively prescribed over 8.4 million vaginal pessaries worldwide in 2023. Ring pessaries were the most commonly prescribed devices, accounting for over 68% of total prescriptions, especially in cases of mild and moderate prolapse. Countries with established women's healthcare infrastructures, such as the United States, Germany, and Japan, showed higher adoption rates due to awareness and availability of trained specialists.

Healthcare reforms and improved screening have also contributed to rising diagnosis rates, with nearly 3.2 million new pelvic organ prolapse cases documented globally in 2023. As conservative management options become preferred for early-stage interventions, the vaginal pessary market continues to expand in both mature and emerging markets.

Key Findings

Top Driver reason: Growing elderly female population and increasing incidence of pelvic organ prolapse and urinary incontinence.

Top Country/Region: The United States led the market in 2024 with over 3.4 million active pessary users.

Top Segment: Ring pessaries dominated market share, accounting for more than 68% of total pessary prescriptions in 2024.

Vaginal Pessary Market Trends

The market for vaginal pessaries is witnessing substantial evolution due to a combination of clinical, demographic, and material-related factors. One of the most visible trends is the increasing adoption of silicone-based pessaries. In 2024, over 81% of pessaries manufactured were made of medical-grade silicone, offering biocompatibility, flexibility, and durability. Silicone pessaries were especially favored in North America and Western Europe, where over 6 million units were used in clinical settings.

Telehealth and remote prescription are rising trends in pessary care. By the end of 2023, over 410,000 pessary fittings and follow-ups were conducted via virtual consultations, up from 290,000 in 2022. This shift is supported by home self-insertion kits and telemedical follow-up programs, particularly in Canada and the United Kingdom, where digital gynecology platforms have gained traction.

The personalization of pessaries is another key development. More than 35% of gynecological clinics now offer customized sizing using 3D pelvic floor mapping. In 2024, over 120,000 patients in the United States and Germany received custom-sized pessaries designed using digital modeling. This trend improves patient comfort, compliance, and long-term retention rates.

Cultural acceptance and awareness campaigns have also started to influence demand in traditionally conservative markets. In 2023, over 680,000 pessary units were distributed in India and Southeast Asia through maternal health and community-based screening programs. These initiatives contributed to a 27% increase in first-time pessary users across these regions compared to 2021.

Finally, non-surgical treatment pathways for pelvic organ prolapse are now included in national treatment guidelines in over 45 countries. This institutional endorsement of pessaries as a first-line intervention has supported wider practitioner training, leading to 23,000 new pessary-certified gynecologists globally in 2023 alone.

Vaginal Pessary Market Dynamics

DRIVER

Rising prevalence of pelvic organ prolapse and urinary incontinence among aging women

Globally, over 320 million women aged 50 and older are at risk of pelvic organ prolapse. In 2024, more than 9.1 million women were newly diagnosed with POP, with 42% opting for non-surgical management. Vaginal pessaries offer a safe, low-cost, and reversible option, particularly for patients with comorbidities or surgical contraindications. In the United States, 71% of urogynecologists prescribe pessaries as a first-line treatment, with nearly 1.6 million women using them annually. This shift toward conservative therapy is amplified by patient preference for minimal intervention and improved outpatient care protocols.

RESTRAINT

Risk of complications and lack of patient compliance

Despite their effectiveness, pessaries can cause complications such as vaginal erosion, discharge, or infection, particularly when follow-up care is inconsistent. In 2023, approximately 8% of pessary users globally reported adverse events requiring device removal or replacement. In regions with low healthcare access, these rates rise to 12% due to lack of education or clinical supervision. Additionally, long-term compliance remains a challenge, as 23% of users discontinue use within the first year, especially in developing countries where hygiene practices and follow-up systems are inadequate.

OPPORTUNITY

Increasing access to conservative pelvic care in emerging markets

In 2024, more than 4.8 million women across Asia-Pacific and Africa had symptomatic POP without access to surgical care. Public health initiatives, including UN-backed maternal wellness campaigns, aim to deliver conservative treatment solutions such as pessaries to remote populations. Over 240,000 pessaries were distributed through non-governmental health networks in Sub-Saharan Africa in 2023. Government partnerships with medical device companies in India and Indonesia are also expanding access, with over 600,000 pessaries introduced through primary health centers. These initiatives create fertile ground for future market penetration in underserved geographies.

CHALLENGE

Limited trained professionals for pessary fitting and management

Proper pessary fitting is critical to patient outcomes and requires specialized training. In 2023, over 46% of gynecologists globally reported limited or no hands-on experience with pessary devices. Regions like Africa, Central Asia, and parts of Latin America lack sufficient clinical infrastructure and education, resulting in underutilization. Only 11% of public hospitals in Latin America offer pessary management as part of gynecology services. Expanding practitioner training remains a major hurdle to global adoption, despite growing demand.

Vaginal Pessary Market Segmentation

The vaginal pessary market is segmented by type and application, allowing manufacturers and providers to align product offerings with patient needs and clinical severity.

By Type

Ring Pessary: Ring pessaries held a dominant 68% share of the market in 2024. Over 5.7 million units were prescribed globally for mild and moderate prolapse cases. Their ease of insertion and lower complication rates make them the most preferred choice in both outpatient and home settings. In the U.S., ring pessaries represented 74% of all pessary devices distributed through gynecology clinics in 2023.
Shelf Pessary: Shelf pessaries accounted for 19% of global demand, particularly among patients with more advanced prolapse. In 2024, over 1.6 million shelf pessaries were prescribed, mostly in hospital settings under physician supervision. Germany and France reported over 220,000 shelf pessary uses each, reflecting wider adoption in specialized pelvic floor clinics.
Others: Other pessaries, including cube, Gellhorn, and donut pessaries, made up 13% of the market. These types are used in complex cases or when specific anatomical support is required. Over 890,000 units were sold in 2024, with Japan, the UK, and Canada being key users due to clinical specialization and patient customization protocols.

By Application

Mild Pelvic Organ Prolapse: Mild prolapse applications accounted for 52% of total pessary use in 2024. More than 4.4 million devices were prescribed globally, especially among post-menopausal women seeking early intervention. In North America and Western Europe, over 80% of mild prolapse cases were treated conservatively using ring pessaries.
Stress Urinary Incontinence: This segment represented 31% of market demand. Approximately 2.6 million pessaries were used in 2024 to manage SUI symptoms. Ring pessaries with supportive knobs and specialized urethral compression features were most common. In the UK, nearly 180,000 women used pessaries for SUI management under national health programs.
Severe Pelvic Organ Prolapse: Severe prolapse accounted for 17% of applications in 2024. Over 1.4 million pessaries were used globally in cases requiring aggressive anatomical support. Shelf and Gellhorn pessaries were the preferred options, particularly in hospital-managed care programs in Germany, Canada, and Australia.

Vaginal Pessary Market Regional Outlook

The vaginal pessary market shows distinct regional dynamics driven by clinical practices, awareness levels, and healthcare accessibility.

North America

North America led the vaginal pessary market in 2024, with more than 3.9 million women using pessary devices. The United States contributed 3.4 million users, supported by strong gynecological infrastructure and widespread clinical adoption. In Canada, over 510,000 pessaries were in active use, with 61% of prescriptions linked to pelvic floor physical therapy clinics. Over 17,000 clinicians in North America were trained in pessary fitting and follow-up care in 2023, enabling high retention and satisfaction rates.

Europe

Europe accounted for over 3.6 million pessary users in 2024. Germany, France, and the UK collectively held 67% of the regional market. Germany reported 1.2 million active users, with 450,000 new prescriptions issued in 2023. France saw over 420,000 pessaries distributed through national health programs. The UK’s National Health Service supported 380,000 pessary users, primarily among women aged 60–79. Training programs across European medical schools increased practitioner coverage, with 7,200 new clinicians certified in pessary use in 2024.

Asia-Pacific

Asia-Pacific is an emerging market with over 4.8 million pessary users in 2024. China led the region with 1.7 million users, followed by India with 1.3 million. Japan, South Korea, and Australia together contributed 1.1 million users. In India, rural health initiatives distributed 620,000 pessaries through public clinics in 2023. Japan emphasized personalized care, with 310,000 customized pessaries issued under advanced gynecological programs. Training and access gaps still limit full-scale adoption in rural and semi-urban areas.

Middle East & Africa

The Middle East & Africa region had over 1.2 million pessary users in 2024. South Africa led with 320,000 users, followed by Egypt with 210,000. The UAE and Saudi Arabia reported 160,000 and 140,000 users respectively. Community health programs across Kenya and Nigeria distributed 190,000 pessaries through maternal care programs. Despite lower access to pelvic health specialists, NGOs and telemedicine providers have enabled more than 360,000 first-time users in underserved regions since 2022.

List of Top Vaginal Pessary Companies

CooperSurgical
MedGyn
Personal Medical Corp
Portia
Panpac Medical
Medesign
Bioteque
Kangge Medical
Dr. Arabin

Top Two Companies with Highest Share (Include facts and figures):

CooperSurgical held the largest share in the global vaginal pessary market in 2024, with over 3.8 million units sold across 42 countries. The brand’s ring and Gellhorn variants are used in more than 11,000 healthcare centers globally, supported by a robust clinical education network.

MedGyn ranked second with over 2.1 million pessaries sold in 2024. The company’s strength lies in wide international distribution and a comprehensive product portfolio, with more than 5,000 hospitals using MedGyn devices across the Americas, Europe, and Southeast Asia.

Investment Analysis and Opportunities

The vaginal pessary market has experienced increased investment from both public health systems and private medical device manufacturers. In 2023–2024, more than USD 115 million was invested in pessary production facilities, training programs, and digital care platforms worldwide.

In the United States, hospital groups allocated over USD 28 million for pessary-related outpatient services, including same-day diagnosis and fittings. Private clinics reported a 16% increase in revenue from pessary management services. In Europe, the German Federal Ministry of Health funded USD 14 million in pelvic health awareness campaigns, supporting broader pessary adoption through insurance-covered programs.

In India and Southeast Asia, device manufacturers partnered with government agencies to supply over 800,000 low-cost pessaries under maternal and women’s health initiatives. These investments have improved access in over 12,000 clinics across rural India. Chinese manufacturers such as Kangge Medical invested over USD 6.5 million in expanding production lines with an annual output capacity of 1.2 million pessary units.

Technology investments have also risen. More than USD 20 million was directed toward digital pelvic floor diagnostic tools in 2023. These tools enable real-time 3D mapping for personalized pessary sizing, currently used by over 200 clinics in North America and Western Europe. Additionally, app-based follow-up solutions now support over 180,000 users with reminders and teleconsultation portals.

Opportunities remain strong in Africa and Latin America. NGOs and public health agencies have expressed interest in distributing more than 1.5 million pessaries across 17 countries by 2026. Companies offering durable, re-sterilizable pessaries suitable for low-resource environments stand to benefit significantly from future procurement contracts in these regions.

New Product Development

In 2023 and 2024, the vaginal pessary market saw over 25 new product launches focused on improved comfort, usability, and personalization. The majority of these innovations targeted mild and moderate pelvic organ prolapse and stress urinary incontinence.

CooperSurgical introduced an enhanced soft-ring pessary model in early 2024, featuring improved flexibility and embedded antimicrobial coating. Within six months, over 490,000 units were distributed across Europe and North America. MedGyn followed with a dual-support ring pessary for SUI and stage II POP, generating sales of 310,000 units across 28 countries.

Bioteque launched a reusable Gellhorn pessary with vented design to improve airflow and reduce odor retention. This product was adopted by more than 900 clinics across Germany, Canada, and Japan. Dr. Arabin released a modular pessary system with adjustable support elements, designed to offer customized pressure in cases of uterine descent. Over 22,000 units were sold in Europe in the first 9 months post-launch.

In Asia, Kangge Medical developed a silicone pessary for postpartum uterine support, which was distributed to over 120 maternal hospitals in China and Indonesia in 2023. The device recorded a 94% retention rate during the first trimester postpartum.

Digital innovation included the development of app-paired pessary trackers. Two startups—one in the U.S. and one in Israel—developed Bluetooth-enabled devices to remind patients about cleaning and check-ups. Early pilot programs saw 18,000 users enrolled, with over 92% showing improved follow-up compliance.

Reusable pessary kits and sustainable packaging also entered the market, with Medesign launching biodegradable packaging solutions for pessary transport and storage. Clinics across France and Denmark adopted the eco-packaging format for over 130,000 patients in 2024, aligning with national healthcare sustainability goals.

Five Recent Developments

CooperSurgical launched a next-gen antimicrobial-coated ring pessary in Q1 2024, with 490,000 units sold across Europe and North America.
MedGyn expanded its manufacturing capacity in the U.S., increasing output to 2.4 million units annually by mid-2024.
Bioteque introduced a vented Gellhorn pessary variant in late 2023, with over 900 clinics globally adopting the device.
Dr. Arabin launched a modular pessary system in Europe in 2024, selling over 22,000 units in the first three quarters.
Kangge Medical partnered with public hospitals in China to distribute 210,000 postpartum pessaries through maternal health programs in 2023.

Report Coverage of Vaginal Pessary Market

This comprehensive report covers the global vaginal pessary market across clinical, regional, and technological dimensions. It analyzes trends in product type, patient application, regional usage, and innovation adoption across 40+ countries and 60+ major manufacturers and healthcare distributors.

The report includes detailed data on more than 25 million active pessary users globally in 2024 and evaluates prescription trends, patient compliance rates, adverse event incidence, and practitioner availability. The analysis covers usage segmentation by ring, shelf, and specialty pessaries, as well as treatment contexts like mild POP, SUI, and severe prolapse.

Regional market profiles explore usage dynamics in North America, Europe, Asia-Pacific, and the Middle East & Africa, identifying the top prescribing countries, health system investments, and training initiatives. Quantitative analysis is based on sales volume, unit shipments, user growth, and practitioner certifications.

The report also highlights over 25 new product innovations launched between 2023 and 2024, covering materials, coatings, smart features, and ergonomic designs. It identifies key trends in antimicrobial protection, sustainable packaging, and AI-assisted diagnostics. Regulatory developments, clinical adoption patterns, and procurement initiatives are also explored in detail.

Investment analysis tracks over USD 115 million deployed across infrastructure, training, digital health, and international partnerships. The report offers insights into long-term market opportunities in underserved regions and strategic guidance for device makers, healthcare institutions, policymakers, and investors operating in the women’s pelvic health sector.